MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to ShareholdersBusiness Wire • 04/01/25
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/27/25
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025Business Wire • 03/25/25
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO ProdrugBusiness Wire • 03/20/25
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIOBusiness Wire • 03/19/25
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer PatientsBusiness Wire • 02/27/25
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung CancerBusiness Wire • 02/26/25
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 MillionBusiness Wire • 02/24/25
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung CancerBusiness Wire • 02/04/25
MAIA Biotechnology Announces Director Participation in Recent Private Placement ClosingsBusiness Wire • 12/19/24
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade GliomasBusiness Wire • 12/16/24
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung CancerBusiness Wire • 12/03/24
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private PlacementBusiness Wire • 11/07/24
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingBusiness Wire • 11/05/24
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/15/24
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung CancerBusiness Wire • 09/10/24
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 09/04/24
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced PatientsBenzinga • 07/23/24